Patients on Apidra insulin (glulisine) may need to switch onto a different method or a different brand of insulin following a technical glitch in the manufacturing process in Frankfurt, Germany. Normal supply is expected to resume around March 2012.
The problems will affect anyone using the Optiset or SoloStar prefilled insulin pens and ClikStar cartridges.
The insulin, made by Sanofi Aventis, is the only medication affected. Users of Lantus and Insuman insulin won't be affected. Separate vials (non-insulin pens) of Apidra have not been affected either and will continue to be available.
You may be required to switch insulin. Your doctor will be able to prescribe a suitable alternative. Most people should be able to switch without problems. In rare cases, where Apidra has been found to be the only suitable insulin, people are advised to speak with their GP about the issue.
Sanofi Aventis have set up a 24 hour support line, 0800 035 25 25, to answer questions and provide information about the supply shortages.
Supply of Apidra insulin affected until March
Thu, 17 Nov 2011
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.
Also related to this storyRapid acting insulins
Insulin pens for diabetes
Insulin side effects
Buy insulin pens
Insulin in the UK
Diabetes and Lantus
Diabetes in India
Diabetes clinical trials
Blood pressure symptoms
Low carb diet
Call for more insulin pumps for treating diabetes in Scotland
Some older diabetes insulin pens taken off market
Study recommends against prescribing analogue insulin for diabetics
Partnership launched to find new diabetes insulin drugs
New disposable diabetes insulin device receives further approval
Stem cell research could help to improve diabetes insulin levels
Size of wrist could indicate a childs insulin resistance
Breakthrough on insulin sensitivity and cholesterol announced
Poor sleep raises diabetic insulin levels, according to study
Call for insulin passports to help diabetes control
Breakthrough in hyperinsulinism research linked to diabetes
Diabetes thrice-weekly insulin drug Degludec shows well in trials
New home urine test helps diabetics with insulin monitoring
Brain insulin could be factor in diabetes risk
Glucagon could become insulin replacement for type 1 diabetes treatment
NHS diabetes treatments ignoring cheaper insulin, according to report
Russia to sell diabetes pig cell insulin therapy, Diabecell
Call for use of insulin pumps for diabetes to be standardised